Keywords: Merck KGaA, Erbitux, Lung cancer, CHMP, EMEA

Merck KGaA gets second CHMP rejection for Erbitux in Advanced Non-Small Cell Lung Cancer

Article | 20 November 2009

• Print This

For the second time this year, the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of German drug major Merck KGaA’s Erbitux (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic non-small cell lung cancer (NSCLC).
The CHMP previously rejected Erbitux in this lung cancer indication in July 2009, stating that the benefits of therapy did not outweigh the risks but, following an appeal from Merck, reviewed the application (The Pharma Letter July 31).

G Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.